BETMAT pushes recombinant endotoxin testing as LAL replacement gains ground

BETMAT is positioning its recombinant cascade reagent assay as a practical path away from horse crab-derived LAL testing for parenteral drugs, biologics and medical devices. The company says the system matches traditional kinetic chromogenic workflows while reducing glucan interference, improving lot consistency and aligning with USP Chapter <86>.

Why it matters: - Pharmaceutical and medical device makers are under pressure to move away from animal-derived endotoxin testing without losing sensitivity or regulatory fit. - BETMAT says its recombinant cascade reagent assay offers a route to animal-free bacterial endotoxin testing that can support quality control, sustainability goals and supply chain stability. - The shift matters because endotoxin control is a core safety requirement for parenteral products, biologics and device manufacturing.

What happened: - BETMAT outlined how its BETMAT rCR assay supports the transition from Limulus Amebocyte Lysate, or LAL, to recombinant endotoxin testing. - The company described the assay as a recombinant cascade system built for kinetic chromogenic bacterial endotoxin testing. - BETMAT linked the timing of the transition to United States Pharmacopeia Chapter <86>, “Bacterial Endotoxins Test Using Recombinant Reagents,” which became effective in May 2025. - BETMAT directed readers to the official website for technical specifications, validation documentation and product listings.

The details: - Traditional LAL testing uses a proteolytic enzyme cascade triggered by Gram-negative bacterial lipopolysaccharides. - Native LAL includes Factor C, Factor B and the proclotting enzyme. - The natural system also includes Factor G, which can respond to (1→3)-β-D-glucans and create non-endotoxin-related interference. - BETMAT says its rCR formulation includes recombinant Factor C, recombinant Factor B and recombinant proclotting enzyme, but excludes Factor G. - That design is intended to reduce false positives tied to glucan contamination from cellulose-based materials, filtration systems or fungal-derived process components. - BETMAT says the assay reproduces the sequential amplification mechanism of natural LAL while using a synthetic chromogenic peptide substrate. - Activated enzyme cleaves the substrate and releases para-nitroaniline, creating a yellow signal measured kinetically at about 405 nm. - The reaction time to a defined absorbance threshold is inversely correlated with endotoxin concentration across the validated range. - BETMAT says the assay is compatible with standard incubating microplate readers and conventional 96-well kinetic chromogenic workflows. - The company says the assay can run with minimal changes to existing laboratory infrastructure. - BETMAT says analytical performance reaches 0.001 EU/mL, with a validated quantitative range typically from 0.001 to 10 EU/mL depending on configuration and instrument settings. - Product suitability studies, including inhibition and enhancement testing, were said to show reliable performance across small-molecule injectables, buffered formulations and biologic products. - BETMAT says the platform is suitable for raw materials, in-process samples, finished formulations, pharmaceutical water systems, cleaning validation samples and selected medical device applications.

Between the lines: - The recombinant approach is meant to preserve the familiar chromogenic LAL workflow while removing the biological variability of horseshoe crab lysate. - A Factor G-free design may reduce false-positive investigations and the operational burden that comes with re-testing and method troubleshooting. - The USP <86> framework gives recombinant methods a clearer compendial path, which should make adoption easier for manufacturers that need validation alignment across regions. - BETMAT is also tying the technology to broader ESG and 3Rs goals, signaling that endotoxin testing is now a quality, regulatory and sustainability issue at once.

What's next: - Adoption will likely depend on method suitability work for specific matrices and on how quickly manufacturers update validated endotoxin programs. - BETMAT says complex sample types may still need standard validation to confirm the absence of assay interference. - Wider use of recombinant reagents will likely track with additional regulatory acceptance and internal quality control decisions across global manufacturing sites.

The bottom line: - BETMAT is pitching rCR as a near drop-in, animal-free alternative to LAL that preserves compendial workflow, reduces glucan interference and supports the industry’s move toward recombinant endotoxin testing.